各类型肺动脉高压的靶向药物治疗  

Targeted drug therapy for various types of pulmonary hypertension

作　　者：殷嘉晨 徐媛[3] 俞砚喆[4] 陈琮玲 丁选胜 张晋萍[3] YIN Jiachen;XU Yuan;YU Yanzhe;CHEN Congling;DING Xuansheng;ZHANG Jingping(Department of Pharmacy,China Pharmaceutical University Nanjing Drum Tower Hospital,Nanjing 210009,Jiangsu Province,China;School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 210009,Jiangsu Province,China;Department of Respiratory and Critical Care Medicine,Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,Jiangsu Province,China;Department of Pharmacy,Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,Jiangsu Province,China)

机构地区：[1]中国药科大学南京鼓楼医院药学部,江苏南京210009 [2]中国药科大学基础医学与临床药学学院,江苏南京210009 [3]南京大学医学院附属鼓楼医院药学部,江苏南京210008 [4]南京大学医学院附属鼓楼医院呼吸与危重症医学科,江苏南京210008

出　　处：《世界临床药物》2023年第12期1330-1334,1338,共6页World Clinical Drug

摘　　要：动脉性肺动脉高压(pulmonary arterial hypertension,PAH)靶向药物自上市以来有效减轻PAH患者临床症状、提高运动耐量,从而显著改善预后。目前,大多数靶向药物研究集中于PAH,对于肺部疾病/缺氧性肺动脉高压、肺动脉阻塞性疾病相关肺动脉高压,PAH靶向药物近年来临床证据也有所增加。基于此,该文对PAH靶向药物对各类肺动脉高压的研究进展作一综述,为临床合理用药提供参考。Target drugs for pulmonary arterial hypertension(PAH) have alleviated the clinical symptoms and improved exercise tolerance,accordingly significantly improved the prognosis of PAH patients since launched into the market.Presently most targeted drugs research focused on PAH.For pulmonary hypertension associated with lung diseases and/or hypoxia,and pulmonary hypertension associated with pulmonary artery obstructions,the clinical treatment evidence of PAH targeted drugs has increased in recent years.Based on this,this article reviewed the progress of PAH targeted drugs on different types of pulmonary hypertension,and provided reference for clinical rational drug use.

关 键 词：肺动脉高压 靶向药物 药物治疗 

分 类 号：R544.1[医药卫生—心血管疾病]